axa framlington health fund presentation final
DESCRIPTION
TRANSCRIPT
SP
Gemma Game, Fund Manager
AXA Framlington Health Fund
May 2012
The team and the Fund Manager
Why healthcare?
Themes
Fund structure
2 14868
Agenda
AXA Framlington Health Fund
The Fund Managers Regional / sector specialists
Linden ThomsonSecondary Fund Manager 7 years’ experience in the Healthcare sector Previously with Hedge Fund Clear River Capital, responsible for fundamental
stock research across the global pharmaceutical and biotechnology sectors. Prior to that with Goldman Sachs based in the healthcare research team with specific focus on the biotechnology sector
BSc in Medical Microbiology from Edinburgh University and is a CFA Charterholder
Gemma GameLead Fund Manager 10 years’ experience managing Global Healthcare Equities Joined AXA Framlington in 2007 and started managing the
AXA WF Healthcare Fund in Q1 2008 Previously Fund Manager on the Global Equities Team at
BlackRock, responsible for investments in the Healthcare sector
BSc in Natural Sciences (Pharmacology) from Cambridge University and is a CFA Charterholder
Chisako HardieJapan20 years
Jeremy GleesonTechnology14 years
Jamie HooperUK Growth14 years
Stephen KellyUS20 years
Julian ThompsonEmerging Markets17 years
Khiem LeEurope Healthcare13 years
3 14868
Fund performance
4 14868
Since inception
Chart source: Lipper. Basis: bid to bid, net income, net of fees to 31/03/2012 in GBP. Indices on a total return (TR) and Capital change (CC), where stated, in GBP. Table source: Lipper & FactSet. Basis: total return, UK tax net, bid to bid, net of fees to 31/03/2012 in GBP. Quartiles based on total return, UK tax net, bid to bid, net of fees, Peer group: Lipper Global Pharma & Health.
Net performance (%) YTD 1Y 3Y (Ann) 5 Y (Ann)
AXA Framlington Health 6.96 8.96 16.36 7.92
MSCI World Healthcare 4.92 13.60 13.48 7.95
Excess over comparative benchmark +2.04 -4.64 +2.88 -0.03
Quartile 2 2 1 1
0
500
1000
1500
2000
2500
Apr-87 Apr-89 Apr-91 Apr-93 Apr-95 Apr-97 Apr-99 Apr-01 Apr-03 Apr-05 Apr-07 Apr-09 Apr-11
AXA Framlington Health Fund S&P 500 Healthcare (TR) NASDAQ Biotech (CC) MSCI Healthcare (TR) Russell 2000 Healthcare (TR)
Investment style
5 14868
Unconstrained investment approach– Benchmark-aware rather than
benchmark-driven
Invest across market cap spectrum
GARP approach – high quality growth companies
Stock selection driven with thematic overlay
Biotechnology Medicaldevices
Pharmaceuticals and
drug delivery
Healthcareservices
Concept: Why healthcare?
6 14868
Top left chart – Source: United Nations Dept of Economic and Social Affairs: “Population Aging and Development 2009”.Top right chart – Source: Wild et al Diabetes Care 27: 1047-1053, 2004.Bottom - Right-hand charts: WHO “World Health Statistics 2011”.
0
2
4
6
8
10
12
14
16
USA
Fran
ceFr
ance
Belg
ium
Sw
itzer
land
Port
ugal
Aust
riaGe
rman
yGr
eece
Denm
ark
Neth
erla
nds
Cana
daNe
w …
Swed
enIc
elan
dSp
ain
Irela
ndIta
ly UKAu
stra
lia
Norw
ayBr
azil
Japa
nCh
ileSl
ovak
iaHu
ngar
yCz
ech …
Pola
ndLu
xem
bou
…Tu
rkey
Mex
ico
Russ
iaCh
ina
Indi
aKo
rea
Healthcare expenditure as % GDP for OECD and BRIC* countries
* Brazil, Russia, India and China
Valuation: P/E ratio of the MSCI World Healthcare Index
7 14868
Source: Bloomberg as at 31/03/2012.
0
5
10
15
20
25
30
35
40
45
50
Jan-95 Jan-97 Jan-99 Jan-01 Jan-03 Jan-05 Jan-07 Jan-09 Jan-11
P/E
ratio
Time
+1 SD
-1 SD
Investment process
8 14868
Healthcare universe
Qualitative
Portfolio <100 stocks
Sell discipline
Re-evaluation offundamentals and valuations
Portfolioconstruction
Fundamental researchindustryanalysis +
company analysis
Quantitative
Current themes
9 14868
Invest in innovationInvest in cost savings and efficiency
Politics: The current US Healthcare System
10 14868
Source: www.house.gov; Patient Protection & Affordable Care Act, P.L. 111-148; Health Care & Education Reconciliation Act, P.L. 111-152.Prepared by: Joint Economic committee, Republican Staff Congressman Kevin Brady, Senior House Republican Senator Sam Brownback, Ranking Member.
Theme 1: Cost savings and efficiency
Why now?– Continuous rise in healthcare spend as % GDP– Healthcare delivery systems across the world are
costly, inefficient and lack transparency
How big is the opportunity?– The National Health Care Anti-Fraud Association
(NHCAA) estimates conservatively that 3% of all health care spending – or $74 billion of the $2.47 trillion spent in 2009 – is lost to healthcare fraud
– Hence eliminating fraud, waste and abuse in the healthcare system could yield significant savings
Beneficiaries include:– Pharmacy Benefit Managers: Medco, Express
Scripts, CVS Caremark– Healthcare IT companies: Cerner, HMS Holdings – Dialysis companies: Fresenius, DaVita– Generics companies: Teva, Mylan, Hikma, Nichi-
Iko
Chart 2: National Health expenditure before and after 2011-2019
Chart 1 – Source: CMS National Health Expenditure (NHE), historical and projected, Goldman Sachs Research estimates, November 2010.Chart 2 – Source: Centers for Medicare & Medicaid Services, Office of the Actuary. he health spending projections are based on the National Health Expenditures released in January 2011. The projections include impacts of the Affordable Care Act.
Chart 1: National health care spending as % of GDP 1960-2019E
National expenditure $bn
0
5
10
15
20
25
1960
1962
1964
1966
1968
1970
1972
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010
2012
2014
2016
2018
%
0
5
10
15
20
25
1960
1962
1964
1966
1968
1970
1972
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010
2012
2014
2016
2018
%
Predicted
4,280.3
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
2011e 2012e 2013e 2014e 2015e 2016e 2017e 2018e 2019e
Total expenditure without Health Reform
4,346.5
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
2011e 2012e 2013e 2014e 2015e 2016e 2017e 2018e 2019e
Total expenditure including Health Reform
CAGR 6.5% CAGR 6.8%
11 14868
Theme 1: Cost savings and efficiency
12 14868
Cost savings & efficiency: Fund share
Cost savings & efficiency relative to MSCI World Healthcare Index
Source: AXA IM as at 05/04/2012.
Generics
Pharmacy Benefit Managers (PBMs)
Dialysis
Healthcare IT
CRO / Outsourcing
Generics 7% PBM
6%
Dialysis 5%
Healthcare IT
3%
CRO/ Outsourcing
1%
2.68%
3.55%
3.54%
0.65%
4.43%
0% 1% 2% 3% 4% 5%
Healthcare IT
Generics
Dialysis
CRO/ Outsourcing
PBM
Theme 1: Cost savings and efficiency
13 14868
Generic utilisation will continue to rise, to near 80% by 2012
Source: *Bloomberg as at 31/03/2012. **AXA IM as at 31/03/2012. Bottom-left: 2011, Credit Suisse estimates 23/03/2011. Bottom-right: Bloomberg as at 30/03/2012. Top-right: Sanford Bernstein, screen print for illustration purposes only.
Express Scripts Pharmacy benefit manager – negotiates drug prices
on behalf of managed care organisations, government programs and large companies
Drives efficiency by increasing penetration ofgenerics, offering mail order prescriptions anddisease management programs
Market cap*: $26.6bn 2013 P/E ratio*: 12.9x 2011–2015 EPS CAGR*: 24% Weight in portfolio**: 4.06%
0
10
20
30
40
50
60
70
80
90
100Generic % of Total Rx
10
20
30
40
50
60
70
Sep-08 May-09 Jan-10 Sep-10 May-11 Jan-12
Shar
e pr
ice
($)
Theme 2: Innovation
BioPharmaceuticals
Significant unmet medical need in key therapeutic areas (for example: Alzheimer’s Disease, cancer, pain, stroke, diabetes and obesity)
Rare genetic diseases create niche markets with attractive pricing for life saving therapies (for example: Gaucher’s Disease, Fabry Disease)
Medical technology
Move towards less invasive surgical procedures improves patient outcomes and reduces cost of care (for example: Minimally Invasive Surgery, robotic surgery)
14 14868
Theme 2: Innovation
15 14868
Innovation: Fund share
Innovation: Relative to MSCI World Healthcare Index
Source: AXA IM as at 05/04/2012.
7.97%
-43.75%
0.53%
0.51%
1.68%
-55% -45% -35% -25% -15% -5% 5% 15%
Biotech
Pharmaceuticals
Speciality Pharma
Medical Instruments
Orthopaedics
Biotechnology
Medical Instruments
Orthopaedics
Specialty Pharmaceuticals
Pharmaceuticals
Biotech 17%
Pharmaceuticals12%
Medical Instruments
8%
Speciality Pharma
7%
Orthopaedics4%
Theme 2: Innovation
Alexion Pharmaceuticals Biotechnology company focussed on treatment for
ultra rare diseases Largest product Soliris treats PNH (paroxysmal
nocturnal hemoglobinuria, a rare blood disorder affecting 8,000–10,000 patients in the US)
Market cap*: $17.2bn 2013 P/E ratio*: 37.2x 2011–2015 EPS CAGR*: 34% Weight in portfolio**: 2.59%
16 14868
Source: *Bloomberg as at 31/03/2012. **AXA IM as at 31/03/2012. Top-right: Soliris mechanism of action, February 2010. Bottom chart: Bloomberg as at 30/03/2012.
0
10
20
30
40
50
60
70
80
90
Sep-08 May-09 Jan-10 Sep-10 May-11 Jan-12
Shar
e pr
ice
($)
Active positions
17 14868
Overweight Underweight
Source: FactSet. Holdings data as at 31/03/2012. Comparative benchmark: MSCI World Healthcare.
NamePortfolio
weight
Comparativebenchmark
weight Difference NamePortfolio
weight
Comparativebenchmark
weight Difference
HMS Holdings Corp. 2.22 -- 2.2 Johnson & Johnson -- 7.21 -7.2
Alexion Pharmaceuticals Inc. 2.58 0.69 1.9 Pfizer Inc. 2.72 6.97 -4.2
BioMarin Pharmaceutical Inc. 1.84 -- 1.8 Sanofi S.A. -- 3.53 -3.5
CVS Caremark Corp. 1.57 -- 1.6 Novartis AG 1.64 5.16 -3.5
Mylan Inc. 1.94 0.40 1.5 Roche Holding AG 1.90 4.89 -3.0
DaVita Inc. 1.87 0.34 1.5 Merck & Co Inc 1.93 4.68 -2.8
Express Scripts Holding Co 2.52 1.00 1.5 GlaxoSmithKline PLC 1.78 4.51 -2.7
Hologic Inc. 1.71 0.23 1.5 Novo Nordisk A/S -- 2.35 -2.4
McKesson Corp. 2.33 0.86 1.5 Bayer AG -- 2.32 -2.3
Cardinal Health Inc. 1.98 0.60 1.4 AstraZeneca PLC -- 2.31 -2.3
TOTAL 20.56 4.11 16.4 TOTAL 9.98 43.94 -34.0
AXA Framlington Health Fund
18 14868
Top ten holdings (%)
Sub-sector split
Source: AXA IM as at 31/03/2012.
UnitedHealth Group Inc. 3.20 HMS Holdings Corp. 2.41
Express Scripts Inc. 2.79 McKesson Corp. 2.22
Celgene Corp. 2.75 Alexion Pharmaceuticals Inc. 2.19
Pfizer Inc. 2.64 Covidien PLC 2.15
Thermo Fisher Scientific Inc. 2.44 Allergan Inc. 2.09
0 5 10 15 20 25 30 35 40 45 50 55 60
Cash
Enabling Technology/Tools
Pharma
Speciality Pharma
Biotech Product
Devices
Healthcare Services
AXA Framlington Health MSCI World Healthcare
Healthcare Services
31%
Devices22%
Biotech Product
17%
Pharma12%
Specialty Pharma
12%
Enabling Technology/
Tools4%
Cash1%
Important notice
AXA Framlington is an expertise of AXA Investment Managers UK Limited. Issued by AXA Investment Managers UK Limited. Registered in England and Wales No: 01431068. Registered Office: 7 Newgate Street, London, EC1A 7NX. Authorised and regulated by the Financial Services Authority. A member of Investment Management Association.
The price of units and the income from them can go down as well as up and investors may not get back the amount originally invested. An initial charge is usually made when you purchase units. Your investment should be for the medium to long term i.e. typically 5–10 years. Past performance is not a guide to future performance. Changes in exchange rates will affect the value of trust investments overseas.
This advertisement is for professional advisers only and must not be relied upon by retail clients. Circulation must be restricted accordingly.
This document does not constitute an offer to sell or buy any units in the Fund. Information relating to investments is based on research and analysis undertaken or procured by AXA Investment Managers UK Limited for its own purposes and may have been made available to other members of the AXA Group of Companies which, in turn, may have acted on it. Whilst every care is taken over these comments, no responsibility is accepted for errors and omissions that may be contained therein. It is therefore not to be taken as a recommendation to enter into any investment transactions.
19 14868
SP
Appendix
Politics: Impact of Health Care Reform
21 14868
Health Care Reform Legislation Element Effective date
1. Medicaid base rebate increase from 15.1% to 23.1% January 1, 2010
2. Change in calculation of Average Manufacturer’s Price (AMP)– “Market basket” price on which Medicaid rebate is calculated– The “market basket” now excludes clinics and hospitals
October 1, 2010
3. Application of Medicaid rebates to Managed Care Organisations March 23, 2010
4. Expansion of Medicaid coverage eligibility from 100% FPL* to 133% January 1, 2014
5. Part D “donut hole” mandatory discount January 1, 2011
6. Public Health Service (340B) program eligibility expansion January 1, 2010
7. Prescription Drug Manufacturers Annual Fee January 1, 2011
Varies by company and exposure therein
* FPL = Federal Poverty Line.
M&A activity: Consolidation continues
22 14868
Source: Bloomberg as at 31/12/2012
$154bn
$105bn $118bn $106bn
$215bn$190bn
$318bn$289bn
$221bn $208bn $216bn $217bn
0
50
100
150
200
250
300
350
0
500
1,000
1,500
2,000
2,500
3,000
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Deal
val
ue ($
bn)
Deal
coun
t
Deal value ($bn) Deal Count